PGEN Looks 47.9% Undervalued on GF Value™ Despite Financial Challenges

gurufocus.com · 2026-09-21

On September 21, 2026, Precigen Inc (NASDAQ: PGEN) announced that the U.S. Food and Drug Administration (FDA) has officially designated its AdenoVerse immunothe

Read the full story at gurufocus.com →